Indian Pharma

In H1FY26, total revenue of the Sai Life Sciences increased by 53% YoY at ₹1,034 crore, driven by healthy growth across both the CRO and the CDMO business.

Patent expiries of blockbuster weight-loss drug semaglutide may create a ₹5,000 crore generic opportunity for Indian pharma firms across India and key emerging and regulated markets

OAI cases nearly halve in 2025, overall inspection volumes also fell 25%

At Pharmexcil's 2025 AGM, industry leaders stressed a shift from volume-led growth to quality, sustainability and market diversification as India's pharma export strategy looks ahead to 2026

India's pharmaceutical industry is stepping into 2026, marking the beginning of a critical five-year period to build the required ecosystem to establish itself as an innovation hub in its bid to become a USD 500 billion sector by 2047, amid near-term challenges of tariff fluctuations and global trade realignments. The predominantly generic medicines-driven domestic drug industry, which has grown from USD 3 billion to USD 60 billion in size over the past 25 years, is shifting towards innovation in next-generation drugs. At the same time, it will also seek to capitalise on the opportunity to capture drugs worth over USD 300 billion that are set to lose exclusivity over the next seven years. "Today, Indian pharma stands at a defining moment and the next 25 years will be shaped by innovation, quality, and access," Indian Pharmaceutical Alliance Secretary General Sudarshan Jain said. The innovation agenda has gained notable momentum among the domestic players, he noted. "From 2026 onwa

Indian cos like Biocon, DRL, Intas, Lupin stand to benefit from the proposed move

Toxic cough syrups have once again proven fatal for children. This time, the tragedy has happened in India. Here's a look at why this sordid tale never seems to let up

The Indian Pharma Market grew 8.7% in August 2025, with the cardiac, anti-diabetic, and anti-neoplastic segments driving growth. Sun Pharma maintained its leadership position

Analysts say Indian pharma firms will increase focus on non-US exports and the domestic market as US tariff threats persist, with firms exploring offshore manufacturing options

Ind-Ra said US tariffs may cause only short-term pricing impact for Indian pharma as firms remain fortified by diversification, strong balance sheets, and global market positioning

Push comes as patents are set to expire in March 2026

As trade tensions escalate under Donald Trump, India finds itself in the crosshairs once again. Donald Trump's proposed duties target two of India's biggest export sectors - pharmaceuticals and copper

Shift is expected to drive a sharp increase in generic drug launches, positioning Indian drugmakers for strong growth

Indian pharma market grew 7.2% in May with strong performance in chronic therapies such as cardiac and anti-infectives, along with gains from price hikes and new launches

The official said industry has raised regulatory hurdles and high cost of certification among other issues in the US as primary obstacles to increasing exports to the US

Trump's executive order, dated May 12, seeks to establish a mechanism through which American patients can buy their drugs directly from the manufacturers

Poly Medicure, a leading medical device company with a dominant position in India's medical consumables market, rallied 5 per cent to ₹2,922 on the BSE in Wednesday's intra-day trade.

Tariff worries, raw material costs still ail sector

Among them, the cardiac, gastrointestinal, and antidiabetic therapies saw high value growth of 9.5 per cent, 9.6 per cent, and 6 per cent, respectively

India has also surpassed the US in the number of FDA-registered generic manufacturing sites